10-Q quarterly report · filed Nov 9, 2026

Editas Medicine, Inc. (EDIT) Q3 2026 10-Q Quarterly Report

Short answer

Editas Medicine, Inc. (EDIT) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $10M (up 37.4% year over year) with net income of −$23M.

Q3 2026 key financials · XBRL

Revenue
$10M
+37.4% YoY · −12.8% QoQ
Net income
−$23M
+6.9% YoY · −28.3% QoQ
Operating margin
-234.3%
EPS (diluted)
−$0.14
+46.2% YoY · +0.0% QoQ

Source: XBRL data from the Editas Medicine, Inc. (EDIT) Q3 2026 10-Q on SEC EDGAR. USD.

Editas Medicine, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $10.4M, up $2.8M from $7.5M YoY, driven by strategic-partner clinical milestones
  • Net loss $23.4M vs $25.1M YoY, with operating expenses $34.6M vs $32.1M
  • Research and development $21.2M, up $1.4M YoY, driven by $3.6M higher sublicense and license fees
  • Cash, equivalents, and marketable securities $190.2M; operating cash outflow $73.8M through nine months
  • EDIT-401 dosing on track for 2026; initial safety data expected first quarter 2027, cash runway into second half of 2028

Risk Factors

  • No updated Risk Factors text provided, so no newly added quarterly risk identified
  • Liquidity risk: accumulated deficit $1.7 billion and substantial additional capital required despite $190.2 million in cash, equivalents, and marketable securities
  • Regulatory and legal risk: Cas9-I patent license disputes require $10.8 million reimbursement payments year-to-date
  • Operational risk: gene-editing programs depend on successful clinical development, regulatory approval, manufacturing, and commercialization
  • Financial risk: DRI revenue-sale liability $56.8 million, with estimated effective interest rate 7.7%

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Editas Medicine, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.